People

HAB Pharma appoints Pankaj Agarwal as CFO

Appointment strengthens the company’s financial management and governance as HAB Pharma advances its next phase of growth

  • By IPP Bureau | September 11, 2026

HAB Pharmaceuticals & Research Limited has appointed Pankaj Agarwal as Chief Financial Officer (CFO). 

The appointment comes as HAB Pharma strengthens its financial and organisational capabilities to support its next phase of growth.

A Chartered Accountant with almost 18 years of experience across the healthcare and pharmaceutical sectors, Pankaj brings expertise in financial strategy, planning and forecasting, financial reporting and compliance, fundraising, treasury management, audit, risk assessment and operational efficiency.  

Prior to joining HAB Pharma, he held senior finance roles at Innovcare Lifesciences, Max Healthcare and Vyome Biosciences.  

At HAB Pharma, Pankaj oversees financial planning, budgeting, reporting, compliance, risk management and corporate governance, while providing financial insights to support informed business decisions. 

He works closely with the leadership team to strengthen financial discipline, operational efficiency and sustainable value creation across the organisation. He is a Chartered Accountant and holds a Post Graduate Executive Management Programme in Finance and Sales from SPJIMR, Mumbai.

Saurabh Agarwal, CEO and Director, HAB Pharma, said “Since joining HAB Pharma in February, Pankaj has brought a strong focus on financial discipline, structured planning and informed decision-making. We are confident that his continued contribution will support HAB Pharma’s growth ambitions and help build a stronger financial and governance framework for the organisation.”

Pankaj Agarwal, Chief Financial Officer, HAB Pharma, said, “Over the past six months at HAB Pharma, it has been an enriching experience to work closely with the leadership team and gain a deeper understanding of the company’s business, operations and growth priorities. The organisation is at an important stage of its evolution, with significant opportunities across manufacturing, R&D, exports and domestic markets. I look forward to continuing 

Upcoming E-conference

ChemPharma R&D Summit 2026

October 27, 2026

Other Related stories

Startup

Digitization